Concurrent chemoradiotherapy with XXXX plus split-dose @entity900 may be an option in inoperable @entity5 : a single-center experience.

@entity1 @entity137 @entity5 @entity900 @entity1149 @entity1206
BACKGROUND: Concurrent chemoradiotherapy is the current standard treatment for inoperable @entity5 ( @entity1149 ). In this study we aimed to investigate the efficacy and @entity137 of CCRT with split dose of @entity900 (30 mg/m2) and @entity1206 (20 mg/m2) in @entity1 with inoperable @entity5 followed in our oncology clinic. MATERIAL AND METHODS: Medical records of 97 @entity1 with inoperable @entity5 treated with concurrent chemoradiotherapy with @entity900 - @entity1206 were retrospectively analyzed. @entity900 (30 mg/m2) and @entity1206 (20 mg/m2) were administered on days 1, 8, 22, and 29 during radiotherapy. Two cycles of consolidation chemotherapy were given. All @entity1 data, including pathological, clinical, radiological, biochemical, and hematological data, were assessed retrospectively using our database system. RESULTS: Our study included 97 unresectable @entity5 @entity1 who were treated with CCRT. Median age was 58 years old (range 39-75) and 87 (89.7%) of the @entity1 were @entity1 . ECOG performance score was 0-1 in 93 @entity1 (95.9%). Squamous histology, the most common histology, was diagnosed in 46 @entity1 (47.4%). Median follow-up time was 23.8 months. Median progression-free survival (PFS) and median overall survival time (OS) were 10.3 months and 17.8 months, respectively. Objective response rate and clinical benefit rate were 75.3% and 83.5%, respectively. Distant and local relapse rate were 57.1% and 42.9%, respectively. Hematological and non-hematological grade 3-4 @entity137 were seen in 13 (13.4%) and 16 (16.5%) @entity1 , respectively. Six (6.1%) @entity1 died due to @entity137 . CONCLUSIONS: The results of this study suggest that split-dose @entity900 may offer fewer grade III-IV @entity137 without sacrificing efficacy and could be an option in @entity1 with inoperable @entity5 during CCRT. Similar to past studies, despite high response rate during CCRT, distant relapse is the major parameter that influences @entity1 survival in long-term in @entity1149 .
